KYMERA THERAPEUTICS INC. - COMMON STOCK

33,27

11-марта-25 16:45:00

15 мин. задержка

Акции

+0,25

+0,76%

Сегодняшний диапазон

31,54 - 33,83

ISIN

N/A

Источник

NASDAQ

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

27 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics to Participate in Upcoming March Investor Conferences

26 фев 2025 07:00:01 Источник Nasdaq GlobeNewswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

20 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics to Participate in Upcoming February Investor Conferences

30 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

14 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

07 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics to Participate in Upcoming December Investor Conferences

26 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics to Participate in Upcoming November Investor Conferences

05 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

31 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

24 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

23 окт 2024 07:15:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

23 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

09 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

25 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics to Participate in Upcoming September Investor Conferences

28 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

21 авг 2024 11:15:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics Announces Pricing of $225 Million Public Offering

19 авг 2024 22:45:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics Announces Proposed Public Offering

19 авг 2024 16:01:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

07 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

31 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.